Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

1. SRPT reported Q1 2025 loss of $3.42 per share, missing estimates. 2. Quarterly revenue was $744.86 million, exceeding expectations. 3. Guidance revised down to $2.3-$2.6 billion from $2.9-$3.1 billion. 4. Elevidys treatment delays expected to persist impacting revenue. 5. Analysts maintain mixed outlooks with significantly lowered price targets.